Compare UBCP & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBCP | ATRA |
|---|---|---|
| Founded | 1902 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.8M | 94.2M |
| IPO Year | 1995 | 2014 |
| Metric | UBCP | ATRA |
|---|---|---|
| Price | $14.31 | $9.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | 7.9K | ★ 36.6K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | ★ 6.67% | N/A |
| EPS Growth | 5.51 | ★ 122.52 |
| EPS | ★ 0.69 | N/A |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | $2.21 | N/A |
| Revenue Next Year | $6.72 | $1,334.59 |
| P/E Ratio | $20.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.55 | $3.92 |
| 52 Week High | $17.34 | $19.15 |
| Indicator | UBCP | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 51.58 |
| Support Level | $14.21 | $8.96 |
| Resistance Level | $16.08 | $11.22 |
| Average True Range (ATR) | 0.51 | 0.67 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 20.81 | 74.49 |
United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. Through its subsidiary (Unified Bank), the company provides a broad range of banking and financial services, which include accepting demand, savings, and time deposits and granting commercial, real estate, and consumer loans. The Company's primary deposit products are checking, savings, and term certificate accounts, and its primary lending products are residential mortgage, commercial, and installment loans. The bank also operates in Marshall County, West Virginia.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.